ClinicalTrials.gg
WithdrawnNCT02792153Updated Aug 24, 2018

Estradiol and Fear Extinction in Anorexia Nervosa (AN)

A Phase 1 interventional study of Estradiol in Anorexia Nervosa, sponsored by Johns Hopkins University. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by Johns Hopkins University · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was withdrawn after 18 months due to lack of recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Enrollment
139th of 143
0 · median 40
Started
2016
with 9 others
Phase 1
14 of 174
none open now
Registered
74th of 174
by date

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 139th largest by enrollment of the 143 interventional ones that give a count, is one of 10 that started in 2016, is one of 14 in phase 1, and was the 74th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether estrogen may help reduce fear of high calorie-density foods in weight-restored women with Anorexia Nervosa (AN).

03

Conditions studied

  • Anorexia Nervosa

Keywords

  • estrogen
  • anxiety
  • amenorrhea
  • eating disorders
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (AN):

  • Previous diagnosis of recent AN with of \<18.5 (within past year)
  • Current BMI > 19.0 and \< 23.0 kg/m2
  • Amenorrhea or oligomenorrhea

Inclusion Criteria (Healthy Controls):

  • BMI > 19 \< 23 kg/m2
  • Taking hormone-based for a period of one month or more
  • Eating disorders symptom scores within one standard deviation of healthy controls

Exclusion Criteria (AN):

  • Any medical or psychiatric problem requiring urgent medical or psychiatric attention, including acute suicidality
  • History of breast cancer, deep vein thrombosis, pulmonary embolism, myocardial infarction or stroke, diabetes, liver disease, known thrombophilic disease
  • Currently taking estrogen or progesterone medication
  • Tobacco use greater than 1 pack per week
  • Use of St. John's Wort, Phenobarbital, phenytoin, carbamazepine, rifampin, and dexamethasone can all decrease plasma estrogen level because they are inducers. Cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice as these may increase plasma estrogen, potentially increasing the presence of side effects
  • Pregnant, lactating or unwilling to use appropriate birth control (which may include abstinence) to prevent pregnancy for the duration of study participation (i.e. up to 4 weeks)
  • Allergy to estradiol or medroxyprogesterone or ingredients in food items used for test meals
  • Undiagnosed, abnormal vaginal bleeding

Exclusion Criteria (Healthy Controls):

  • Ever diagnosed with an Eating Disorder
  • Any medical or psychiatric problem requiring urgent medical or psychiatric attention, including acute suicidality
  • Pregnant, lactating or unwilling to use appropriate birth control (which may include abstinence) to prevent pregnancy for the duration of study participation (i.e. up to 4 weeks)
  • Food allergies to items in the test meal
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Estrogen

    AN participants receive a course of transdermal estradiol treatment.

    Drug: Estradiol

Interventions

  • AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.

    Also known as: Climara

06

What researchers measure

Primary outcomes

  1. Electrodermal skin conductance activity (EDA) during a test meal

    Meal-related anxiety will be estimated from EDA recordings during a 90 minute test meal session pre- and post-treatment (day 1 and day 21). EDA will be reported as the rate of peaks (\>0.02 microsiemens) per second and the average skin conductance level (in microsiemens).

    Time frame: Baseline (day 1) and post-treatment (day 21)

Secondary outcomes

  1. Heart rate variability during a test meal

    Variability in heart rate will be measured by the variation in interpeak (beat-to-beat) interval during the 90 minute test meal session pre- and post- treatment (day 1 and day 21).

    Time frame: Baseline (day 1) and post-treatment (day 21)

  2. Subjective ratings of anxiety

    Visual analog scales will be used to assess self-report anxiety at multiple points (time 0 min, 5 min, 10 min, 20 min, 30 min, 50 min, 70 min and 90 min) during the 90 minute test meal session pre- and post-treatment (day 1 and day 21).

    Time frame: Baseline (day 1) and post-treatment (day 21)

  3. Salivary cortisol concentration during a test meal

    The concentration of salivary cortisol will be assessed at multiple points (time 0 min, 5 min, 10 min, 20 min, 30 min, 50 min, 70 min and 90 min) during the test meal session. Test meals occur twice during the entire length of the study on day 1 and day 21. The cortisol response will be reported as area under the curve.

    Time frame: Baseline (day 1) and post-treatment (day 21)

07

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Aug 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
Jun 7, 2016
Start
Dec 2016
Primary completionActual
Aug 22, 2018
CompletionActual
Aug 22, 2018
Last update
Aug 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02792153
Responsible party
Sponsor
First posted
Jun 7, 2016
Start date
Dec 2016
Primary completion
Aug 22, 2018
Completion
Aug 22, 2018
Last update
Aug 24, 2018

Study contacts

Angela Guarda, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion